New Approaches in the Treatment of Obstructive Sleep Apnea

Understanding the Potential of Innovation in OSA Management Originally published on the National Sleep Foundation website as part of Sleep Awareness Week 2023.   As part of Sleep Awareness Week®, we welcome the contributions and perspectives of our sponsors....

Apnimed to Participate in the SVB Securities Global Biopharma Conference

 CAMBRIDGE, Mass. January 25, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and related disorders, including its lead oral treatment candidate AD109,...

Apnimed Completes Oversubscribed $79.75 Million Series C Extension Financing to Fund Two Planned Phase 3 Trials of AD109, an Oral Medication with the Potential to Be the First Therapy for Direct Treatment of Obstructive Sleep Apnea (OSA)

– Phase 3 Trials Expected to Begin Enrollment in Second Quarter of 2023, Subject to Discussions with the FDA  CAMBRIDGE, Mass. January 3, 2023 – Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment...

Apnimed to Present at the Stifel Healthcare Conference

CAMBRIDGE, Mass. November 8, 2022 – Apnimed, a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies to address obstructive sleep apnea (OSA) and related disorders, including its lead candidate AD109, today announced that management...

Stifel Healthcare Conference

Wednesday, November 16 at 4:10pm to 4:40pm ET LISTEN TO THE WEBCAST or VIEW THE PRESENTATION News 2020 2021 2022 Events Insights Past...